Advanced Dry Macular Degeneration Clinical Trial
Official title:
The Role of Alpha Melanocyte Stimulating Hormone in Ocular Disease
| Verified date | December 2022 |
| Source | Duke University |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The purpose of this study is gain a better understanding of a molecule called alpha melanocyte stimulating hormone (alpha MSH) and its potential role in your retinal disease. Alpha MSH has been shown to have an important role in the regulation of ocular immunity in animal models of inflammatory retinal diseases and retinal dystrophies, and there may be a protective effect of alpha MSH. By studying the levels of alpha MSH in your eye we may better understand its role in advanced dry macular degeneration. By studying the levels of this molecule we hope to better understand if it may be a good target for future treatment.
| Status | Completed |
| Enrollment | 54 |
| Est. completion date | October 19, 2021 |
| Est. primary completion date | October 19, 2021 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | 60 Years and older |
| Eligibility | Inclusion Criteria: - 60 years or older - diagnosis of advanced dry macular degeneration with foveal geographic atrophy - limited vision or blindness (20/100 or worse) in that eye - pseudophakia (prior cataract surgery in that eye) Exclusion Criteria: |
| Country | Name | City | State |
|---|---|---|---|
| United States | Duke University Eye Center | Durham | North Carolina |
| Lead Sponsor | Collaborator |
|---|---|
| Duke University |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Level of Alpha Melanocyte Stimulating Hormone as Measured by Enzyme-linked Immunosorbent Assay | 2 hours |